En esta página
01ABUS precio
02Instantánea
03Gráfico
04Divisiones de acciones
05Acerca de
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
18Activistas y propietarios del %+ 5
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
23Noticias
26Mis Métricas
ABUS Arbutus Biopharma Corporation - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 12, 2026
$4,45
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$3,67mínimo 52 semanas
$5,45máximo 52 semanas
Capitalización Bursátil (MRQ)
$879M
P/E (TTM)
5.6
BPA (TTM)
$0.79
Ingresos (TTM)
$182M
tus insignias
Rango 52S
$4–$5
Calificación del Analista
STRONG BUY
Precio Objetivo
$5
P/E
5.6
ROE
89.6%
Margen de Beneficio Neto
84.2%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
ABUS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$4.45
Capitalización Bursátil (MRQ)
$879M
P/E (TTM)
5.6
BPA (TTM)
$0.79
Ingresos (TTM)
$182M
ROE (TTM)
89.6%
Rango 52S
$4–$5
ABUS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Divisiones de acciones
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 4 de noviembre de 2010 | 1-for-5 | Inversa |
Acerca de Arbutus Biopharma Corporation - Common Stock Descripción general de la empresa de Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
sectorHealthcare
industriaBiotechnology
empleados19
paísCA
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$14M2016-12-31 → 2025-12-31
BPA$-0.172016-12-31 → 2025-12-31
Flujo de caja libre$-40M2016-12-31 → 2025-12-31
Margen neto84.2%2016-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | ABUS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | 5.6promedio 5A ≈-10.5 | ≈-10.5 | · | · | |
| P/S (TTM) | 4.8promedio 5A ≈50.1 | ≈50.1 | 10.3 | Infravalorado | |
| P/C (MRQ) | 3.4promedio 5A ≈5.7 | ≈5.7 | 3.7 | Valor razonable | |
| Price / FCF (Precio / FCF) | -22.1promedio 5A ≈-11.3 | ≈-11.3 | · | · | |
| Price / Cash Flow (Precio / Flujo de Caja) | -22.1promedio 5A ≈-11.3 | ≈-11.3 | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 11.4promedio 5A ≈5.7 | ≈5.7 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | ABUS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | 82.0%promedio 5A ≈-555.0% | ≈-555.0% | -588.2% | En línea | |
| EBITDA Margin (Margen EBITDA) | -271.0%promedio 5A ≈-555.0% | ≈-555.0% | -588.2% | En línea | |
| Margen de Beneficio Neto (TTM) | 84.2%promedio 5A ≈-528.9% | ≈-528.9% | -507.2% | En línea | |
| ROA (TTM) | 81.1%promedio 5A ≈-40.5% | ≈-40.5% | -29.6% | En línea | |
| ROE (TTM) | 89.6%promedio 5A ≈-55.0% | ≈-55.0% | -42.0% | En línea |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | ABUS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 81.4promedio 5A ≈9.7 | ≈9.7 | 9.6 | Liquidez sólida | |
| Quick Ratio (Ratio Rápido) | 15.5promedio 5A ≈9.5 | ≈9.5 | 6.6 | En línea |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | ABUS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 128.2%promedio 5A ≈64.5% | ≈64.5% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | -28.8%promedio 5A ≈-2.8% | ≈-2.8% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | 15.3% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | ABUS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.1promedio 5A ≈0.1 | ≈0.1 | 0.2 | Débil | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 7.3promedio 5A ≈13.3 | ≈13.3 | · | · | |
| Revenue / Employee (Ingresos / Empleado) | ≈$741.2K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
581.5%
Próximo informe
Nov 11, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 4, 2026 | $-0.03 | $-0.02 | -47.1% |
| 31 de marzo de 2026 | May 12, 2026 | $1.19 | $-0.03 | 3988.9% |
| 31 de diciembre de 2025 | $-0.02 | $-0.04 | 44.0% | |
| 30 de septiembre de 2025 | $-0.04 | $-0.03 | -26.6% | |
| 30 de junio de 2025 | $0.01 | $-0.05 | 120.6% | |
| 31 de marzo de 2025 | $-0.13 | $-0.11 | -23.2% | |
| 31 de diciembre de 2024 | $-0.07 | $-0.08 | 14.2% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.40 | $0.51 | $0.62 | $0.87 | $1.17 | $1.14 | · | $3.61 | $3.31 | $3.70 | · | |
| Revenue / Share | $0.07 | $0.03 | $0.11 | $0.26 | $0.10 | · | · | $0.11 | $0.20 | $0.03 | · | |
| Cash Flow / Share | $-0.21 | $-0.35 | $-0.52 | $-0.23 | $-0.64 | · | · | $-1.23 | $-0.89 | $-1.09 | · | |
| Cash / Share | $0.09 | $0.19 | $0.15 | $0.20 | $0.75 | $0.58 | · | $0.67 | $0.99 | $0.43 | · | |
| EPS (TTM) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-1.32 | $-1.21 | $-1.56 | $-7.24 | $-1.38 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | · | 191,778,950 | 191,551,282 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | · | 191,778,950 | 192,399,733 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.31 | $1.32 | · | $0.40 | $0.43 | $0.41 | · | $0.56 | $0.65 | $0.64 | · | $0.71 | $0.81 | $0.87 | · | $0.95 | |
| Revenue / Share | $0.01 | $0.92 | · | $0.00 | $0.06 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.03 | $0.03 | $0.04 | · | $0.04 | |
| Cash Flow / Share | · | $-0.04 | · | · | · | $-0.07 | · | · | · | $-0.11 | · | · | · | $-0.17 | · | · | |
| Cash / Share | $0.10 | $0.12 | · | $0.12 | $0.20 | $0.19 | · | $0.17 | $0.33 | $0.24 | · | $0.10 | $0.16 | $0.25 | · | $0.16 | |
| EPS (TTM) | $0.79 | $0.83 | · | $-0.23 | $-0.29 | $-0.41 | · | $-0.43 | $-0.45 | $-0.44 | · | $-0.45 | $-0.45 | $-0.45 | · | $-0.48 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $182M | $191M | · | $15M | $15M | $6M | · | $7M | $10M | $13M | · | $22M | $24M | $33M | · | $36M | |
| Net Income TTM | $153M | $161M | · | $-42M | $-54M | $-77M | · | $-77M | $-77M | $-74M | · | $-75M | $-73M | $-70M | · | $-69M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 6.1 | 5.4 | · | -19.7 | -10.7 | -8.5 | · | -9.0 | -6.9 | -5.9 | · | -4.5 | -5.1 | -6.7 | · | -4.0 | |
| P/S | 5.2 | 4.6 | · | 59.7 | 38.4 | 104.4 | · | 108.2 | 58.0 | 35.8 | · | 15.3 | 16.3 | 15.1 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| Earnings Yield | 16.5% | 18.4% | · | -5.1% | -9.4% | -11.8% | · | -11.2% | -14.6% | -17.1% | · | -22.2% | -19.6% | -14.8% | · | -25.1% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $14M | $6M | $18M | $39M | $11M |
| Margen Operativo % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Beneficio neto | $-34M | $-70M | $-73M | $-69M | $-76M |
| EPS Diluido | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Ratio Rápido | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-40M | $-65M | $-87M | $-36M | $-68M |
Propietarios institucionales (13F) 187 declarantes · $719.6M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
187
Valor en tenencia
$719.6M
Nuevas posiciones
35
Posiciones cerradas
23
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 35 (+3 vs trimestre anterior) | 23 (-8 vs trimestre anterior) | 62 (+13 vs trimestre anterior) | 42 (-10 vs trimestre anterior) | +466K |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Two Seas Capital LP | $91 658 798 | 19 095 583 | 12,74% | Acciones |
| MORGAN STANLEY | $84 951 868 | 17 698 305 | 11,81% | Acciones |
| Whitefort Capital Management, LP | $75 812 453 | 15 794 261 | 10,54% | Acciones |
| BlackRock, Inc. | $66 077 140 | 13 766 071 | 9,18% | Acciones |
| VANGUARD GROUP INC | $44 456 122 | 9 242 437 | 6,18% | Acciones |
| STATE STREET CORP | $37 772 059 | 7 869 179 | 5,25% | Acciones |
| Rubric Capital Management LP | $36 158 098 | 7 532 937 | 5,03% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $33 651 259 | 7 010 679 | 4,68% | Acciones |
| BARCLAYS PLC | $20 197 987 | 4 207 914 | 2,81% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $19 769 043 | 4 117 691 | 2,75% | Acciones |
| GOLDMAN SACHS GROUP INC | $16 832 650 | 3 506 802 | 2,34% | Acciones |
| BANK OF AMERICA CORP /DE/ | $12 701 745 | 2 646 197 | 1,77% | Acciones |
| BlackBarn Capital Partners LP | $12 000 000 | 2 500 000 | 1,67% | Acciones |
| Legal & General Group Plc | $11 837 409 | 2 466 127 | 1,65% | Acciones |
| Woodline Partners LP | $10 952 909 | 2 281 856 | 1,52% | Acciones |
| Jefferies Financial Group Inc. | $8 216 026 | 1 711 672 | 1,14% | Acciones |
| NOMURA HOLDINGS INC | $7 857 989 | 1 637 081 | 1,09% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7 398 998 | 1 541 458 | 1,03% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6 869 846 | 1 431 218 | 0,95% | Acciones |
| NORTHERN TRUST CORP | $6 811 315 | 1 419 024 | 0,95% | Acciones |
| OSAIC HOLDINGS, INC. | $6 469 756 | 1 347 866 | 0,90% | Acciones |
| ADAR1 Capital Management, LLC | $6 087 106 | 1 268 147 | 0,85% | Acciones |
| Deltroit Asset Management (UK) LLP | $5 760 000 | 1 200 000 | 0,80% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $5 449 738 | 1 135 362 | 0,76% | Acciones |
| CITIGROUP INC | $4 220 338 | 879 237 | 0,59% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3 771 945 | 838 210 | 0,52% | Acciones |
| BANK OF MONTREAL /CAN/ | $3 734 102 | 777 938 | 0,52% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3 123 360 | 650 700 | 0,43% | Acciones |
| MACKENZIE FINANCIAL CORP | $2 946 269 | 613 806 | 0,41% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2 889 638 | 602 008 | 0,40% | Acciones |
| Western Standard LLC | $2 605 378 | 542 787 | 0,36% | Acciones |
| Rangeley Capital, LLC | $2 400 000 | 500 000 | 0,33% | Acciones |
| Nuveen, LLC | $2 383 723 | 496 609 | 0,33% | Acciones |
| Man Group plc | $2 272 642 | 473 467 | 0,32% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $2 215 900 | 461 646 | 0,31% | Acciones |
| Bank of New York Mellon Corp | $2 179 752 | 454 115 | 0,30% | Acciones |
| CenterBook Partners LP | $2 136 725 | 445 151 | 0,30% | Acciones |
| Freestone Capital Holdings, LLC | $2 124 000 | 442 500 | 0,30% | Acciones |
| CITADEL ADVISORS LLC | $1 942 541 | 404 696 | 0,27% | Acciones |
| KENNEDY CAPITAL MANAGEMENT LLC | $1 849 430 | 385 298 | 0,26% | Acciones |
| D. E. Shaw & Co., Inc. | $1 832 942 | 381 863 | 0,25% | Acciones |
| Swiss National Bank | $1 375 200 | 286 500 | 0,19% | Acciones |
| Ledgewood Wealth Advisors, LLC | $1 336 493 | 278 436 | 0,19% | Acciones |
| FMR LLC | $1 282 503 | 267 188 | 0,18% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $1 265 688 | 263 685 | 0,18% | Acciones |
| Carrera Capital Advisors | $1 234 402 | 257 167 | 0,17% | Acciones |
| Quinn Opportunity Partners LLC | $1 225 027 | 255 214 | 0,17% | Acciones |
| Invesco Ltd. | $1 204 353 | 250 907 | 0,17% | Acciones |
| UBS Group AG | $1 196 198 | 249 208 | 0,17% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $1 161 682 | 242 017 | 0,16% | Acciones |
Activistas y propietarios del %+ 5 8 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 presentaciones | 28 de abril de 2026 | 8,00% | Enmienda | · | SEC |
| Roivant Sciences Ltd. ×14 presentaciones | 25 de febrero de 2025 | 20,50% | Enmienda | · | SEC |
| Patrick Machado ×4 presentaciones | 17 de julio de 2019 | · | Presentación inicial | · | SEC |
| Dr. Andrew Lo ×5 presentaciones | 17 de julio de 2019 | · | Presentación inicial | · | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 presentaciones | 12 de julio de 2019 | · | Presentación inicial | · | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 presentaciones | 12 de julio de 2019 | · | Presentación inicial | · | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 presentaciones | 12 de julio de 2019 | · | Presentación inicial | · | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 presentaciones | 12 de julio de 2019 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 35 insiders · 17 directivos · 19 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Lindsay Androski | President and CEO | 18 de septiembre de 2026 M | 72 337 | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Interim President & CEO | 14 de febrero de 2025 A | 1 658 003 | 0 | 0 | $0 |
| William H. Collier | President and CEO | 1 de febrero de 2023 A | 216 500 | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 de marzo de 2019 A | 341 396 | 0 | 0 | $0 |
| Tuan Nguyen | Chief Financial Officer | 18 de septiembre de 2026 M | 159 963 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 14 de febrero de 2025 A | 249 824 | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 de marzo de 2017 A | · | 0 | 0 | $0 |
| Karen Sims | Chief Medical Officer | 14 de febrero de 2025 A | 155 494 | 0 | 0 | $0 |
| Christopher J. Naftzger | General Counsel and CCO | 14 de febrero de 2025 A | 140 544 | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 de febrero de 2024 A | 1 485 121 | 0 | 0 | $0 |
| Elizabeth Howard | EVP, GC, Compliance | 1 de febrero de 2023 A | 86 024 | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 20 de enero de 2022 A | · | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 de diciembre de 2018 A | · | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 de abril de 2018 A | · | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 de marzo de 2017 A | · | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 de agosto de 2016 M | 42 097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 de marzo de 2016 A | · | 0 | 0 | $0 |
| Roger Sawhney | Consejero | 18 de septiembre de 2026 M | 30 825 | 0 | 0 | $0 |
| Robert A Beardsley | Consejero | 18 de septiembre de 2026 M | 32 276 | 0 | 0 | $0 |
| Anuj Hasija | Consejero | 18 de marzo de 2025 A | · | 0 | 0 | $0 |
| Keith S Manchester | Consejero | 14 de agosto de 2024 M | 46 069 | 0 | 0 | $0 |
| Melissa Rewolinski | Consejero | 23 de mayo de 2024 A | · | 0 | 0 | $0 |
| Frank Torti | Consejero | 23 de mayo de 2024 A | · | 0 | 0 | $0 |
| James R Meyers | Consejero | 23 de mayo de 2024 A | · | 0 | 0 | $0 |
| Daniel D Burgess | Consejero | 23 de mayo de 2024 A | · | 0 | 0 | $0 |
| Richard C Henriques JR | Consejero | 23 de mayo de 2024 A | 1 000 | 0 | 0 | $0 |
| Tram Tran | Consejero | 25 de mayo de 2022 A | · | 0 | 0 | $0 |
| Andrew Cheng | Consejero | 3 de junio de 2021 A | · | 0 | 0 | $0 |
| Myrtle S Potter | Consejero | 17 de agosto de 2019 A | · | 0 | 0 | $0 |
| Vivek Ramaswamy | Consejero | 19 de junio de 2018 A | · | 0 | 0 | $0 |
| Herbert J Conrad | Consejero | 19 de junio de 2018 A | · | 0 | 0 | $0 |
| Frank Karbe | Consejero | 21 de junio de 2017 A | · | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Propietario del 10% | 18 de octubre de 2021 C | 38 847 462 | 0 | 0 | $0 |
| Andrew Lo | Propietario del 10% | 12 de enero de 2018 P | · | 0 | 0 | $0 |
| Patrick Machado | Propietario del 10% | 12 de enero de 2018 P | · | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 26 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,68% | 72 962 NS | 31 de julio de 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 521 191 NS | 31 de julio de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,47% | 23 611 SH | 2 de octubre de 2026 | Diario |
| IWC · iShares Trust | 0,19% | 545 721 SH | 11 de septiembre de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,11% | 124 896 NS | 31 de julio de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,06% | 14 124 SH | 2 de octubre de 2026 | Diario |
| IBB · iShares Trust | 0,06% | 1 201 130 SH | 11 de septiembre de 2026 | Diario |
| IWO · iShares Trust | 0,05% | 1 506 889 SH | 11 de septiembre de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,05% | 172 487 SH | 19 de agosto de 2026 | Diario |
| PWS · Pacer Funds Trust | 0,03% | 1 706 NS | 31 de julio de 2026 | N-PORT |
| IWM · iShares Trust | 0,03% | 4 035 105 SH | 11 de septiembre de 2026 | Diario |
| RSSL · Global X Funds | 0,02% | 76 843 NS | 31 de julio de 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 120 110 SH | 2 de octubre de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 925 044 SH | 19 de agosto de 2026 | Diario |
| ISCG · iShares Trust | 0,01% | 24 707 SH | 11 de septiembre de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1 810 587 SH | 19 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,01% | 430 244 SH | 19 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,01% | 11 624 SH | 9 de septiembre de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 66 333 NS | 31 de julio de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 265 986 SH | 11 de septiembre de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 49 783 SH | 9 de septiembre de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5 034 547 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13 683 SH | 19 de agosto de 2026 | Diario |
| ISCB · iShares Trust | · | 6 673 SH | 11 de septiembre de 2026 | Diario |
| ISCV · iShares Trust | · | 13 314 SH | 11 de septiembre de 2026 | Diario |
| SMMV · iShares Trust | · | 60 845 SH | 1 de septiembre de 2026 | Diario |
ABUS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 7 analistas
COMPRA
Objetivo mediano
$5.39
+21,0%
3 42,9%
Compra fuerte
3 42,9%
Compra
1 14,3%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
1 analistas · 2026-09-28Objetivo medio $5.39 +21,0%
Mín$5.39
Media$5.39
Máx$5.39
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 12, 2026